[Skip to Navigation]
June 22, 2020

Alternative Payment Models—Victims of Their Own Success?

Author Affiliations
  • 1Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania
  • 2Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 3Healthcare Transformation Institute, University of Pennsylvania, Philadelphia
JAMA. 2020;324(3):237-238. doi:10.1001/jama.2020.4133
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    2 Comments for this article
    Bundles Moderating Medicare Costs or Contributing to a Cost Shift?
    Joel James, MA | Multi-Specialty Medical Group Practice
    These models may be be worth preserving but at what expense? Physicians will not continue to invest capital, resources, and labor into voluntary, Federal-run experiments whose policy rules change frequently. Any long-run planning is nearly impossible and incentives for participating evaporate the more successful you are at reducing cost. If V-B care as defined by CMS/CMMI is to be widely adopted I believe it will have to be mandatory. Also, the authors are basing their premise of the apparent impact on healthcare costs on the fact that the HC cost/GDP has leveled off at 18% - as have Medicare expenditures since ACA passage. But that’s only part of the story. Aside from the fact, which the authors recognize, that GDP registered historically strong growth since the great recession ended in 2010 (over 20%), when looking at personal consumption expenditures for healthcare that expenditure rise has been pretty much unabated through 2019. See eg https://fred.stlouisfed.org/series/DHLCRC1Q027SBEA

    Could this mean that Medicare VB care models have perhaps helped to stabilize the growth in Medicare expenditures (as the researchers contend) but costs have shifted more into commercial sector – contributing to the continuous rise on HC PCE? If so, what is really gained? – perhaps a possible slight moderation in cost growth in Medicare but a not-so insignificant cost shift to commercial, non-Medicare payers and patients.
    CONFLICT OF INTEREST: Employed by medical group which is also a BPCI-A participant and convener
    Financial Barriers to Expensive Care
    Gordon Moore, MD | Harvard Medical School
    Am I missing something? Most Medicare Advantage members face steep first dollar costs, totalling thousands of dollars for hospital care. The levels of out-of-pocket cost exposure have been rising. Wouldn't these be a potential factor in flattening the cost curve?